185 related articles for article (PubMed ID: 24587193)
1. Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study.
Persson M; Elfström KM; Brismar Wendel S; Weiderpass E; Andersson S
PLoS One; 2014; 9(2):e90023. PubMed ID: 24587193
[TBL] [Abstract][Full Text] [Related]
2. Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological Abnormalities.
Johansson H; Bjelkenkrantz K; Darlin L; Dilllner J; Forslund O
PLoS One; 2015; 10(4):e0124460. PubMed ID: 25893988
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of women with ASCUS or LSIL pap smears at baseline and HPV E6/E7 mRNA positive: a 3-year follow-up.
Bruno MT; Ferrara M; Fava V; Barrasso G; Panella MM
Epidemiol Infect; 2018 Apr; 146(5):612-618. PubMed ID: 29465024
[TBL] [Abstract][Full Text] [Related]
5. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
6. [Clinical effect evaluation of high risk human papilloma virus E6/E7 mRNA in triaging women with atypical squamous cells of undetermined significance].
Guo Z; Zhao DM; Zhang SK; Wu ZN; Sun XB; Jia MM; Chen Q; Guo LW; Chen PP; Zhang JG
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1094-1099. PubMed ID: 34695901
[No Abstract] [Full Text] [Related]
7. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of HPV E6/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears.
Ren C; Zhu Y; Yang L; Zhang X; Liu L; Ren C
Arch Gynecol Obstet; 2018 Feb; 297(2):425-432. PubMed ID: 29143102
[TBL] [Abstract][Full Text] [Related]
9. Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS.
Zhu Y; Ren C; Yang L; Zhang X; Liu L; Wang Z
BMC Cancer; 2019 Mar; 19(1):271. PubMed ID: 30917784
[TBL] [Abstract][Full Text] [Related]
10. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
[TBL] [Abstract][Full Text] [Related]
11. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
12. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
Persson M; Brismar Wendel S; Ljungblad L; Johansson B; Weiderpass E; Andersson S
Oncol Rep; 2012 Jul; 28(1):346-52. PubMed ID: 22484610
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US).
Waldstrom M; Ornskov D
Cytopathology; 2012 Dec; 23(6):389-95. PubMed ID: 21933290
[TBL] [Abstract][Full Text] [Related]
15. The clinical application of HPV E6/E7 mRNA testing in triaging women with atypical squamous cells of undetermined significance or low-grade squamous intra-epithelial lesion Pap smear: A meta-analysis.
Yang L; Zhu Y; Bai Y; Zhang X; Ren C
J Cancer Res Ther; 2017; 13(4):613-620. PubMed ID: 28901302
[TBL] [Abstract][Full Text] [Related]
16. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than Papanicolaou screening for women regardless of age.
Pierry D; Weiss G; Lack B; Chen V; Fusco J
Arch Pathol Lab Med; 2012 Aug; 136(8):956-60. PubMed ID: 22849745
[TBL] [Abstract][Full Text] [Related]
17. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
[TBL] [Abstract][Full Text] [Related]
18. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
[TBL] [Abstract][Full Text] [Related]
19. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.
Sørbye SW; Arbyn M; Fismen S; Gutteberg TJ; Mortensen ES
PLoS One; 2011; 6(10):e26022. PubMed ID: 21998748
[TBL] [Abstract][Full Text] [Related]
20. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.
Alaghehbandan R; Fontaine D; Bentley J; Escott N; Ghatage P; Lear A; Coutlee F; Ratnam S
Diagn Cytopathol; 2013 Sep; 41(9):767-75. PubMed ID: 23341349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
